Bile Duct Cancer Market, by Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine and 5 fluorouracil (5-FU), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy (Pembrolizumab (Phase 3)

Bile Duct Cancer Market, by Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine and 5 fluorouracil (5-FU), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy (Pembrolizumab (Phase 3) and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Bile duct cancer, also known as cholangiocarcinoma, is a type of cancer that forms in the bile ducts. The symptoms of bile duct cancer may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever.
Increasing prevalence of bile duct cancer has driven the market growth, For instance, according to American Cancer Society report 2018, each year around 8,000 people in the U.S. are diagnosed with cholangiocarcinoma. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers.
Market Dynamics
Key players are focusing on product approvals to strengthen their position in the global bile duct cancer market. In February 2021, Eisai Co., Ltd., a pharmaceutical company, received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its Fibroblast Growth Factor (FGF) receptor selective tyrosine kinase inhibitor E7090.
Key features of the study:
This report provides an in-depth analysis of the global bile duct cancer market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bile duct cancer market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market
Detailed Segmentation:
Global Bile Duct Cancer market, By Treatment Type:
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
Global Bile Duct Cancer market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Bile Duct Cancer market, By Region:
North America
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Incyte Corporation*
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Eisai Co., Ltd.
QED Therapeutics, Inc.
Agios Pharmaceuticals, Inc.
RenovoRx
Ability Pharmaceuticals
Imbrium Therapeutics L.P.
Delcath Systems, Inc.
“*” marked represents similar segmentation in other categories in the respective section.